Press Releases

Press Releases

View all news
Voronoi Licenses Out Autoimmune Disease Therapy in KRW 380 Billion Deal
2021.09.01
⚫ DYRK1A-targeting drug that restores immune system balance by regulating T cells

Voronoi Inc. (CEOs Daekwon Kim and Hyuntae Kim), a company specializing in the development of precision targeted therapies, announced on the 1st that it has licensed out its autoimmune disease therapy program to Brickell Biotech in a deal with an upfront payment of USD 5 million and a total deal size of up to USD 323.5 million.
Brickell, listed on NASDAQ in the U.S., has a management team with experience in the development and commercialization of autoimmune disease therapies for psoriasis, ulcerative colitis, Crohn's disease, and other conditions at global pharmaceutical companies such as Eli Lilly, Novartis, and Allergan. Brickell is currently conducting a Phase 3 clinical trial for a hyperhidrosis treatment in the U.S.
Inhibiting the DYRK1A kinase, which is responsible for intracellular signaling, suppresses the differentiation of helper T cells, which play a key role in exacerbating inflammation, and promotes the differentiation of regulatory T cells, which calm inflammation, thereby inducing the restoration of a disrupted immune balance. Based on this mechanism of action (MOA), Brickell plans to develop the program as a treatment for autoimmune diseases, neuroinflammation, and other conditions. A Phase 1 clinical trial will be conducted in 2022. Robert Brown, CEO of Brickell Biotech, said, "We are confident that a drug with a novel mechanism that restores a disrupted immune system can improve the lives of millions of patients suffering from inflammatory diseases. This will be an opportunity to strengthen our dermatologic inflammation franchise while also expanding the company's capabilities into inflammation more broadly." CEO Daekwon Kim of Voronoi said, "We are pleased to partner with the experienced team at Brickell. We will continue to deliver results in the field of precision targeted therapies, including EGFR C797S and HER2+."